1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Japan 2022 Review/Outlook: Supply Crisis, Incentives, Cost Controls In Focus

Balance Of Give And Take

 
• By Lisa Takagi

As Japan's pharma market continues to face supply chain challenges and rising healthcare costs, regulatory authorities are looking to policies that balance incentives in critical areas and temporary price rises with other other ongoing measures to contain the national drugs bill. The Pink Sheet takes a look at the key changes last year and what to expect in 2023.

Japan 2022/2023
Japan announced its plan for the "mid-year" pricing review for FY2023 • Source: Shutterstock

Japan’s pharmaceutical industry continued to suffer from a years-long distribution crisis in 2022, which especially affected generic products despite a year that saw surging demand from medical institutions amid repeated local waves of the COVID-19 pandemic.

Meanwhile, the country's health and regulatory authorities have decided to press ahead with another annual drug reimbursement price revision this April, although to minimize the impact associated with the pandemic, along with rising fuel costs and a weaker

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By Lisa Takagi

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.